Cytotoxic Cells: Recognition, Effector Function, Generation, and Methods 1993
DOI: 10.1007/978-1-4684-6814-4_41
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Trials of Immunotherapy of Cancer Utilizing Cytotoxic Cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2003
2003
2003
2003

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 117 publications
0
1
0
Order By: Relevance
“…This allows the TCRs from any cloned T cell to be cloned and incorporated into a gene vector. The suitability of T lymphocytes as a target for retroviral transduction has been demonstrated in a number of human gene therapy protocols such as transduction with the adenosine deaminase (ADA) gene in patients with ADA deficiency and transduction of tumour infiltrating lymphocytes with IL‐1β, IL‐12 or the neo marker [19–21]. The efficient transfer of TCRs from melanoma, human immunodeficiency virus and EBV‐specific T cells has demonstrated the general applicability of TCR transfer [10, 17, 22].…”
Section: Discussionmentioning
confidence: 99%
“…This allows the TCRs from any cloned T cell to be cloned and incorporated into a gene vector. The suitability of T lymphocytes as a target for retroviral transduction has been demonstrated in a number of human gene therapy protocols such as transduction with the adenosine deaminase (ADA) gene in patients with ADA deficiency and transduction of tumour infiltrating lymphocytes with IL‐1β, IL‐12 or the neo marker [19–21]. The efficient transfer of TCRs from melanoma, human immunodeficiency virus and EBV‐specific T cells has demonstrated the general applicability of TCR transfer [10, 17, 22].…”
Section: Discussionmentioning
confidence: 99%